Business Overview: Sotera Health Company (NASDAQ: SHC)

---

Executive Summary

Sotera Health Company is a global, mission-critical provider of sterilization, lab testing, and advisory services to the healthcare industry, operating under the banner "Safeguarding Global Health." Through three segments — Sterigenics, Nordion, and Nelson Labs — the company sits deep inside the supply chain of nearly every major medical device and pharmaceutical maker: it serves over 40 of the top 50 medical device companies and nine of the top ten pharmaceutical companies by revenue, operating 62 facilities across more than a dozen countries.

FY2025 marked the company's 20th consecutive year of revenue growth, with net revenues of $1.164 billion. But Sotera Health's story cannot be told without its single largest overhang: multi-year ethylene oxide (EO) tort litigation tied to its Sterigenics sterilization facilities, which has already produced hundreds of millions of dollars in settlements and judgments and remains a live, unresolved risk.

---

1. Core Business Model & How They Work

Sotera Health is fundamentally an outsourced, regulated infrastructure provider — customers cannot easily bring sterilization or Co-60 isotope supply in-house, and switching sterilization methods or vendors requires lengthy regulatory re-validation.

[ Medical Device / Pharma Manufacturer ] ➡️ [ Outsourced Sterilization (Sterigenics) ] ➡️ [ FDA/Regulatory-Cleared Product ] ➡️ [ Market ]
                                                        ▲
                                          [ Co-60 Isotope Supply (Nordion) ]
                                                        
[ Device/Drug in Development ] ➡️ [ Outsourced Micro & Analytical Testing (Nelson Labs) ] ➡️ [ Regulatory Submission ]

Key Operational Drivers

1. Regulated switching costs. Once a customer validates a product's sterilization process with a specific Sterigenics facility, re-validating with a new provider is costly and time-consuming, creating durable customer relationships.
2. Scarce isotope supply. Nordion is one of a limited number of global suppliers of Cobalt-60, the radioactive isotope essential to gamma sterilization and some cancer treatments — about 90% of Nordion's 2025 revenue came from multi-year contracts, and the company estimates roughly 20% (potentially rising to ~50% in some years) of its long-term Co-60 supply comes from Russian reactors, a geopolitical exposure unique to this niche.
3. Three-pronged service bundle. Sterigenics (sterilization), Nordion (isotope/irradiation systems), and Nelson Labs (micro and analytical lab testing) let Sotera sell adjacent, cross-referral services to the same medical device and pharma customer base.
4. EO litigation overhang. A substantial and recurring use of cash and management attention goes toward settling and defending ethylene oxide tort claims tied to emissions from Sterigenics facilities, most prominently in the Chicago-area Willowbrook, Illinois and Atlanta, Georgia communities.

---

2. Business Segments

                         Sotera Health Company
                                  │
        ┌─────────────────────────┼─────────────────────────┐
        ▼                         ▼                         ▼
   Sterigenics               Nordion                   Nelson Labs
 (gamma/EO/E-beam         (Co-60 isotope supply      (micro & analytical
  sterilization;           + irradiation systems)     chemistry testing;
  48 facilities,                                       ~3,000 customers,
  13 countries,                                        ~600 scientists)
  2,000+ customers)
  FY25 Rev: $756M            FY25 Rev: $188M            FY25 Rev: $220M
  (+8.3% y/y)                (+8.2% y/y)                (-3.9% y/y)

---

3. Product Portfolio

---

4. Competitive Landscape

• Sterilization services: STERIS plc is the largest direct competitor across contract sterilization, with its own gamma, EO, and e-beam capacity; smaller regional players and in-house sterilization at large device makers also compete, but regulatory re-validation costs make customer switching rare once established.
• Isotope supply: Nordion competes with a small number of global Co-60 producers; the extremely limited number of reactors capable of producing medical/industrial-grade Co-60 makes this a structurally concentrated market.
• Lab testing: Nelson Labs competes with other outsourced testing labs (e.g., Pace Analytical, WuXi AppTec's testing operations) and with in-house testing capabilities at larger device/pharma companies.

---

5. Strategic Strengths & Risks

Strengths

• Deep, sticky customer relationships driven by regulatory re-validation costs that make switching providers expensive and slow.
• 20 consecutive years of revenue growth, with FY2025 Adjusted EBITDA margin of 51.0% — an unusually high-margin profile for an industrial services business.
• Essential-infrastructure positioning: sterilization is a legally mandated step for most single-use medical devices, making demand relatively non-discretionary.

Risks

• Ethylene oxide tort litigation is the single largest risk: a 2022 Willowbrook, Illinois trial produced a $358.7 million judgment (including $320 million in punitive damages); the company subsequently settled Willowbrook-area claims for $408.0 million in 2023, with further settlements in 2025 and 2026, plus a $35 million Atlanta settlement in 2023. Roughly 450 personal injury and 305 property devaluation claims tied to Atlanta remain pending, and environmental liability insurance does not cover EO claims.
• Single-source supply risk: the company relies on a single EO supplier in the U.S. and a limited number of nuclear reactors for Co-60, with meaningful exposure to Russian-sourced isotope supply amid sanctions risk.
• Tightening regulation of EO and radiation, including the EPA's NESHAP rule and a FIFRA interim decision, could raise compliance costs or constrain capacity.
• High leverage and sponsor influence: the company remains significantly influenced by its financial sponsors, Warburg Pincus and GTCR.

---

6. Financial Overview

---

7. Summary Conclusion

Sotera Health occupies a structurally advantaged position at a mandatory, hard-to-replicate chokepoint in the medical device and pharmaceutical supply chain, evidenced by two decades of uninterrupted revenue growth and a 51% Adjusted EBITDA margin. The company's core competitive strength — deeply entrenched, regulation-driven customer switching costs — is real and durable. However, the ongoing ethylene oxide tort litigation is not a peripheral risk but a central, recurring claim on cash flow and management attention, with hundreds of millions already paid and material exposure (roughly 750 pending claims tied to the Atlanta area alone) still unresolved. Investors are effectively underwriting both an attractive, moat-protected industrial-services business and an open-ended legal liability whose ultimate size is difficult to bound.